Infinium Pharmachem reported an 18.3% rise in consolidated net profit to ₹1215.02 lakh for the year ended March 31, 2026, compared to ₹814.53 lakh in the previous year. Revenue from operations for the period increased 21.8% to ₹18963.17 lakh from ₹15570.92 lakh in FY25. The company's Board of Directors approved the audited standalone and consolidated financial results at a meeting held on May 29, 2026.

The standalone financial results showed a net profit of ₹1001.74 lakh for FY26, up from ₹846.89 lakh in the prior year. Standalone revenue from operations grew to ₹15644.64 lakh from ₹13691.64 lakh. Total income for the year stood at ₹15785.65 lakh, while total expenses were ₹14434.19 lakh. The Board noted that there was no deviation in the utilization of funds raised through IPO and preferential issues.

Consolidated Performance

On a consolidated basis, total income rose to ₹19176.96 lakh for the year ended March 31, 2026, up from ₹15782.53 lakh in the previous year. Total expenses increased to ₹17392.92 lakh from ₹14625.53 lakh. Profit before tax for the year was ₹1784.04 lakh, compared to ₹1157.00 lakh in FY25. The earnings per equity share (basic) for the year increased to ₹7.80 from ₹5.60 in the previous year.

The company operates in a single business segment, Intermediate Chemicals. The consolidated financial statements include results from subsidiaries Infinium Green Energy Private Limited, Infinium Healthcare Private Limited, and Shanghai Tajilin Industrial Co. Limited.

Financial Position and Cash Flows

The company's total consolidated assets as of March 31, 2026, stood at ₹17493.60 lakh, a decrease from ₹19838.52 lakh in the previous year. Total equity increased to ₹1740.81 lakh from ₹1533.98 lakh. Cash and cash equivalents at the end of the year were ₹2978.05 lakh, down from ₹3484.00 lakh at the beginning of the year.

M/s Ashok Rajpara & Co, Chartered Accountants, the statutory auditors, issued an audit report with an unmodified opinion on the standalone and consolidated financial results. The Board also approved criteria for granting omnibus approval for related party transactions for FY26-27 and took note of the temporary closure of operations pursuant to a Gujarat Pollution Control Board order and its subsequent revocation.

Infinium Pharmachem has announced the resumption of business operations at its manufacturing facility located at Plot 38-39 GIDC, Sojitra. This development follows the acceptance of a revocation application by the Gujarat Pollution Control Board (GPCB), which subsequently issued an order revoking the earlier closure direction.

Revocation Details

The GPCB issued the Revocation Order under Section 33(A) of the Water (Prevention and Control of Pollution) Act, 1974. The company confirmed receipt of this order on May 20, 2026. As per the communication, the company has ensured compliance with the conditions stipulated in the revocation order to facilitate the restart of operations.

Operational Resumption

Consequent to the regulatory approval, Infinium Pharmachem stated that it will commence regular manufacturing and operational activities at the Sojitra plant starting May 20, 2026. The management is undertaking necessary steps to ensure a smooth transition back to full production while adhering to all applicable statutory and regulatory requirements.

Key Regulatory Information

The following table outlines the specific details regarding the regulatory order and its impact on the company's operations: